AUS
NZ
UK
CA
USA
IND
Highlights:
-
GSK PLC has reached a $2.2 billion settlement that addresses 93% of the ongoing litigation related to its heartburn medication Zantac, which is viewed as a favorable outcome by analysts.
-
The settlement includes a $70 million payment to Valisure and is expected to positively impact GSK's share price by approximately 10%.
-
Analysts from Jefferies and UBS express that the settlement alleviates a significant overhang on the stock, while still raising concerns about sales expectations for the RSV vaccine, Arexvy, and the sustainability of Shingrix's growth.
GSK PLC {NYSE:GSK} has secured a $2.2 billion settlement to resolve approximately 93% of the litigation concerning its heartburn medication, Zantac. Analysts at Jefferies consider this outcome to be a near-best-case scenario, falling at the lower end of their anticipated liability costs, which ranged from $2 billion to $3.5 billion. The settlement is also accompanied by a $70 million agreement related to a complaint filed by Valisure, a lab that raised concerns regarding the drug.
At the time of reporting, GSK's shares experienced a 4% increase, trading at 1,520p. Jefferies predicts that the settlement could contribute roughly 10% to GSK's share price. The broker notes that plaintiff firms are unanimously advising their clients to accept the settlement terms, with full implementation expected by the end of the first half of 2025. This settlement is expected to mitigate the overhang from the Zantac litigation on GSK’s stock.
Jefferies also highlighted that the $2.3 billion non-core charge includes estimates for the remaining 6,000 cases, primarily concentrated in Delaware State Court, where no trials are currently scheduled before March 2025. GSK had initially planned to address the larger plaintiff firms first, leaving the smaller cases for later.
In addition to the positive implications of the settlement, Jefferies and UBS have raised concerns about GSK’s future sales expectations, particularly regarding its RSV vaccine, Arexvy, over the next eighteen months. There is ongoing debate regarding the sustainability of Shingrix’s growth as well.
UBS considers the settlement to be a significant positive development, alleviating major uncertainties for investors. The timing of the settlement came earlier than market expectations, which anticipated a resolution only after a ruling from the Delaware Supreme Court. UBS also notes that while the $2.2 billion settlement value is at the lower end of expectations based on prior product litigation settlements in the pharmaceutical industry, GSK has expressed confidence in resolving the remaining cases.
While Jefferies maintains a "buy" rating with a price target of 2,000p, UBS adopts a "neutral" rating with a target of 1,580p, reflecting the need for caution regarding GSK's sales outlook in light of ongoing concerns.
